Skip to main
NAGE

ChromaDex Corp (NAGE) Stock Forecast & Price Target

ChromaDex Corp (NAGE) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Niagen Bioscience is currently a leader in NAD+ science and healthy-aging research, with a strong portfolio of patented molecules and a unique platform focused on boosting NAD+ levels. The launch of their clinician-directed telehealth platform and the recent sale of their Analytical Standards & References business fortify their position in the market. Additionally, a potential favorable outcome for their lawsuit against the FDA and the potential for expansion into new retail channels provide significant growth opportunities for the company. With a strong financial outlook, including projected revenue growth of 10-15%, gross margins of 63.5%, and potential for increased earnings and profits, Niagen Bioscience presents an attractive risk/reward opportunity for investors.

Bears say

Niagen Bioscience is at risk due to the highly competitive nature of the health and wellness market, potential changes in consumer preferences, and the reliance on one key product. Regulatory and stock dilution risks could also negatively impact the company's financials and potential for growth, especially given the recent failed study for Parkinson's. These factors, along with a discount rate of 12.5% and high market entry probability, lead to a negative outlook on the company's stock.

ChromaDex Corp (NAGE) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ChromaDex Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ChromaDex Corp (NAGE) Forecast

Analysts have given ChromaDex Corp (NAGE) a Strong Buy based on their latest research and market trends.

According to 2 analysts, ChromaDex Corp (NAGE) has a Strong Buy consensus rating as of Aug 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ChromaDex Corp (NAGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.